ZYBT vs TAOP vs CLPS vs VNET

For growth investors, CLPS Incorporation (CLPS) is the stronger pick with 15.

2% revenue growth year-over-year, versus -16. 0% for Taoping Inc. (TAOP). VNET Group, Inc. (VNET) offers the better valuation at 92. 4x trailing P/E (29. 6x forward), making it the more compelling value choice. Analysts rate VNET Group, Inc. (VNET) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, VNET Group, Inc.

(VNET) delivered a total return of -65. 1%, compared to -99. 9% for Taoping Inc. (TAOP). Over 10 years, the gap is even starker: VNET returned -37. 2% versus TAOP's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), CLPS Incorporation (CLPS) is the lower-risk stock at 0.

19β versus VNET Group, Inc. 's 2. 66β — meaning VNET is approximately 1264% more volatile than CLPS relative to the S&P 500. On balance sheet safety, Zhengye Biotechnology Holding Limited (ZYBT) carries a lower debt/equity ratio of 25% versus 3% for VNET Group, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), CLPS Incorporation (CLPS) is pulling ahead at 15.

2% versus -16. 0% for Taoping Inc. (TAOP). On earnings-per-share growth, the picture is similar: VNET Group, Inc. grew EPS 103. 8% year-over-year, compared to -1870. 0% for Taoping Inc.. Over a 3-year CAGR, VNET leads at 10. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Zhengye Biotechnology Holding Limited (ZYBT) is the more profitable company, earning 6.

1% net margin versus -32. 7% for Taoping Inc. — meaning it keeps 6. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ZYBT leads at 8. 8% versus -29. 0% for TAOP. At the gross margin level — before operating expenses — ZYBT leads at 49. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, CLPS (14.

6% yield), ZYBT (5. 3% yield) pay a dividend. TAOP, VNET do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, CLPS Incorporation (CLPS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

19), 14. 6% yield). Taoping Inc. (TAOP) carries a higher beta of 2. 26 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CLPS: -78. 6%, TAOP: -99. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ZYBT (Healthcare) and TAOP (Technology) and CLPS (Technology) and VNET (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ZYBT is a small-cap income-oriented stock; TAOP is a small-cap quality compounder stock; CLPS is a small-cap high-growth stock; VNET is a small-cap quality compounder stock. ZYBT, CLPS pay a dividend while TAOP, VNET do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.